Clinical Trials on Neoplasms, Plasma Cell

Total 110343 results

Emory University
National Cancer Institute (NCI); Takeda; National Institutes of Health (NIH); Janssen...

Active, not recruiting

Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE)

Plasma Cell Myeloma

United States
Sanofi

Completed

SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (PomdeSAR)

Plasma Cell Myeloma

United States
Mayo Clinic
Arizona State University

Completed

Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma

Multiple Myeloma | Plasma Cell Disorder

United States
University of Arkansas
University of Iowa

Not yet recruiting

High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders

Plasma Cell Disorder
Robert Flavell, MD, PhD
National Cancer Institute (NCI)

Recruiting

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Multiple Myeloma | Plasma Cell Myeloma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); GlaxoSmithKline

Recruiting

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Plasma Cell Myeloma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission

Plasma Cell Myeloma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Pilot Trial of Homebound Stem Cell Transplantation

Plasma Cell Dyscrasia

United States
Sanofi

Active, not recruiting

Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)

Plasma Cell Myeloma

Mexico, Sweden, Poland, France, Czechia, Greece, Taiwan, Lithuania, Portugal, Spain, Australia, Italy, New Zealand, Russian Federation, Turkey, Japan, United States, Belgium, China, Denmark, Germany
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Amgen

Active, not recruiting

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma

Plasma Cell Myeloma

United States
Sanofi

Active, not recruiting

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA)

Plasma Cell Myeloma

France, United States, Australia, Brazil, Canada, Czechia, Greece, Hungary, Italy, Japan, Korea, Republic of, New Zealand, Russian Federation, Spain, Turkey, United Kingdom
Thomas Jefferson University
Janssen Scientific Affairs, LLC

Active, not recruiting

Home Based Daratumumab Administration for Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Withdrawn

Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma

Plasma Cell Myeloma

United States
Sanofi

Completed

Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM)

Plasma Cell Myeloma

France, Spain, Greece, Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Denmark, Germany, Hungary, Italy, Japan, New Zealand, Norway, Poland, Portugal, Russian Federation, Slovakia, Sweden, Taiwan, Turkey, United...
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Lenalidomide Maintenance in Plasma Cell Myeloma

Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

Plasma Cell Myeloma

United States
Sanofi

Completed

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Plasma Cell Myeloma

France, Italy, Czechia, Greece, Spain, Canada, Australia, United States, Brazil, Hungary
Roswell Park Cancer Institute

Completed

Fermented Milk Supplementation on Symptoms of Disease and Treatment in Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
Ohio State University Comprehensive Cancer Center

Completed

Daratumumab in Treating Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Plasma Cell Myeloma

United States
University of Texas Southwestern Medical Center

Completed

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Withdrawn

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myeloproliferative Disorders | Solid Tumor | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Nausea and Vomiting
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Sanofi

Recruiting

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Plasma Cell Myeloma

Czechia, Australia, Chile, France, Spain, United States, Brazil, China, Greece, Japan, Korea, Republic of, Sweden, Taiwan, Finland, Italy, Russian Federation
Mayo Clinic

Recruiting

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Plasma Cell Myeloma

United States
Sanofi

Recruiting

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (IONA-MM)

Plasma Cell Myeloma

Germany, United States, Argentina, China, France, Hong Kong, Italy, Japan, Puerto Rico, Spain, Switzerland, United Arab Emirates, United Kingdom, Austria, Belgium, Netherlands, Taiwan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

Plasma Cell Myeloma

United States
Sanofi

Completed

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

Plasma Cell Myeloma

France, Germany, Italy, Spain
Sanofi

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

Plasma Cell Myeloma

United States, Czechia, France
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

Plasma Cell Myeloma

United States
Roswell Park Cancer Institute

Completed

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United States
M.D. Anderson Cancer Center

Recruiting

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Lymphoma | Leukemia | Plasma Cell Myeloma | Central Nervous System Lymphoma | Secondary Central Nervous System Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Nonmalignant Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Nonmalignant Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

No longer available

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Secondary Myelofibrosis

United States
Vanderbilt University
National Cancer Institute (NCI)

Completed

Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Nonmalignant Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms | Methemoglobinemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

Myeloma-Multiple | Myeloma, Plasma-Cell

United States
University of California, San Francisco

Withdrawn

Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy

Lymphoma | Leukemia | Plasma Cell Dyscrasia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Completed

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

Myeloma-Multiple | Myeloma, Plasma-Cell

United States
Vanderbilt University
National Cancer Institute (NCI)

Terminated

Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Chronic Myeloproliferative Disorders | Cancer Survivor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Sanofi

Not yet recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (SubQSA)

Plasma Cell Myeloma Refractory
University of Chicago
National Cancer Institute (NCI); Multiple Myeloma Research Foundation

Active, not recruiting

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Plasma Cell Myeloma | Residual Disease

United States
University of Colorado, Denver

Terminated

Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Refractory Plasma Cell Myeloma

United States
Masonic Cancer Center, University of Minnesota

Completed

T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma | Plasma Cell Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Monoclonal Gammopathy of Undetermined Significance | Smoldering Plasma Cell Myeloma

United States

Clinical Trials on Neoplasms, Plasma Cell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations